Boothbay Fund Management’s Tempest Therapeutics TPST Stock Holding History

Boothbay Fund Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,866	Closed	-$20.2K	–	1787
2024 Q4	$20.2K	Sell	1,866 -24	-1%	-$310	﹤0.01%	1418
2024 Q3	$34.4K	Hold	1,890	–	–	﹤0.01%	1532
2024 Q2	$53.8K	Hold	1,890	–	–	﹤0.01%	1407
2024 Q1	$96.1K	Hold	1,890	–	–	﹤0.01%	1424
2023 Q4	$108K	Buy	+1,890	New	+$89.5K	﹤0.01%	1422
2021 Q3	–	Sell	-806	Closed	-$117K	–	2180
2021 Q2	$117K	Hold	806	–	–	﹤0.01%	1712
2021 Q1	$189K	Buy	806 +735	+1,035%	+$297K	0.01%	1378
2020 Q4	$30K	Hold	71	–	–	﹤0.01%	1197
2020 Q3	$23K	Sell	71 -462	-87%	-$157K	﹤0.01%	1010
2020 Q2	$183K	Buy	+533	New	+$213K	0.01%	808

Other funds holding TPST

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's TPST Position: Q1 2025 in Review

Boothbay Fund Management sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 1,866 shares — an estimated $20.2K sold.

Boothbay Fund Management first reported a position in TPST in Q2 2020 and held it in 10 quarters. The position peaked at $189K in Q1 2021. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

Boothbay Fund Management reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 1,866 Tempest Therapeutics shares in Q1 2025, an estimated $20.2K.
Boothbay Fund Management first reported a position in Tempest Therapeutics in Q2 2020 and held it in 10 quarters.
Boothbay Fund Management's Tempest Therapeutics position peaked at $189K in Q1 2021.
23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.